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Abstract  
Background 
Pharmacological doses of glucocorticoids (GC) reduce inflammation and preserve muscle 
function in boys with Duchenne muscular dystrophy (DMD). Delayed puberty and bone 
fragility are consequences of GC treatment. The aim of this study was to determine the 
acceptability of a 2-year pubertal induction regimen using 4-weekly testosterone injections 
and examine changes in physique, bone integrity, muscle pathology (assessed by magnetic 
resonance imaging) and muscle function.  
Methods 
15 prepubertal males with DMD, aged 12-17 years and receiving GC, were treated with an 
incremental testosterone regimen for 2 years. Participants completed a Treatment 
Satisfaction Questionnaire (TSQM). Data on BMI, bone density, muscle pathology and 
function were collected at baseline and 2 years later.  
Results 
Testosterone injections were well tolerated, with high TSQM scores. Baseline BMI z-score 
was 2.16 (0.90) and 1.64 (1.35) 2 years later. Median testosterone levels were 9.7nmol/l 
(IQR 5.7-11.1) 6 – 9 months after the last injection with an associated increase in testicular 
volume. Lumbar spine z-score was 0.22 (SD 2.21) at baseline and 0.35 (SD 2.21) after 2 years. 
Upper and lower limb muscle contractile cross sectional area increased in all participants 
during the trial (p=0.05 and p<0.01 respectively). There was a reduction in T2 relaxation 
times in most muscle groups with stable upper limb muscle function.  
Conclusion 
Incremental monthly testosterone injections were well tolerated, promoted endogenous 
testosterone production and had a positive impact on the skeleton and contractile muscle 
bulk with evidence suggesting a beneficial impact on the underlying disease process.  
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Introduction 1 
Duchenne muscular dystrophy (DMD) is a life-limiting genetic disorder that affects 1 in 2 
approximately 4000 newborn boys in the UK and occurs due to mutations in the DMD gene 3 
(1). Absence of the gene product, dystrophin, leads to increased muscle cell fragility and a 4 
cycle of degeneration and repair with inflammatory change and  replacement of muscle 5 
fibres with fibrosis and fat (2). Pharmacological doses of glucocorticoids (GC) – either 6 
prednisolone or deflazacort – have had a beneficial impact on longevity and quality of life in 7 
DMD (3). Glucocorticoids stabilise muscle strength and have positive effects on 8 
cardiovascular and respiratory function (4) and help to reduce scoliosis (5). Unfortunately 9 
long-term high dose GC therapy has side-effects that include slow growth, weight gain, 10 
osteopaenia, secondary hypoadrenalism (6) and effects on mood (7). GC also prevent the 11 
normal progression into puberty, which can have significant psychological consequences.  12 
Exogenous androgen has been used for many years in boys with pubertal delay and is 13 
increasingly being used in adolescents with DMD (8). Exogenous androgen can have an 14 
anabolic effect on a range of different tissues and could mitigate some of the deleterious 15 
effects of GC on muscle, bone and psychological well-being. The increased life expectancy 16 
and changing expectations of adolescents with DMD underlines the importance of effective 17 
DMD management at this time. As yet, no one has examined the psychological, 18 
developmental and skeletal effects of testosterone in a prospective manner with a detailed 19 
examination of bone and muscle phenotype. A retrospective audit identified 14 boys who 20 
had been treated with testosterone for induction of puberty and highlighted the lack of 21 
consensus in terms of regimen, length of treatment or age at initiation (8). This study 22 
investigated the efficacy and tolerability of a 2-year regimen of incremental, intramuscular 23 
testosterone to induce puberty in a cohort of GC-treated adolescents with DMD.  24 
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Methods 25 
Participants 26 
Participants were from a single centre study that followed 15 adolescents with DMD and 27 
delayed puberty as they were treated with testosterone. Full details of the clinical trial and 28 
protocol have been published (9). Briefly, 15 prepubertal males between 12 and 17 years old 29 
were treated with a stepwise regimen of testosterone injections every 4 weeks. Data were 30 
collected to determine the effectiveness and tolerability of the treatment regimen. Inclusion 31 
and exclusion criteria are in the Supplementary Methods section. 32 
 33 
Outcomes 34 
Primary outcome 35 
The primary outcome measure was Treatment Satisfaction Questionnaire for Medication 36 
(TSQM) (10).  37 
Secondary outcomes 38 
The secondary outcome measures were:  39 
• Auxological assessment including height, weight and pubertal status  (11) 40 
• Biochemical assessment of pubertal stage 41 
• Bone age  42 
• Muscle cross-sectional area (CSA), contractile cross-sectional area (cCSA) and fat 43 
fraction (FF) determined by muscle MRI of upper and lower limbs, and T2 relaxation 44 
time of the upper limb 45 
• Motor performance evaluated using  North Star Ambulatory Assessment (NSAA) and 46 
Performance of Upper Limb (PUL)  47 
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• Bone mineral adjusted density of the lumbar spine and total body (minus head) using 48 
Dual-energy x-ray absorptiometry (DXA) 49 
 50 
Testosterone regimen 51 
The incremental testosterone regimen involved the administration of testosterone 52 
(Sustanon 250) by deep intramuscular injection over a 2-year period: 53 
• Sustanon 50 mg (0.2 ml) every 4 weeks for 12 weeks 54 
• Sustanon 100 mg (0.4 ml) every 4 weeks for 40 weeks 55 
• Sustanon 150 mg (0.6 ml) every 4 weeks for 24 weeks 56 
• Sustanon 250 mg (1 ml) every 4 weeks for 28 weeks 57 
 58 
Assessment 59 
Patient satisfaction 60 
The TSQM is self-administered and used at baseline and  6 monthly thereafter. It is a 14-item 61 
instrument, yielding four subscale scores: global satisfaction, effectiveness, adverse events 62 
and convenience and has been validated for adults with chronic disease (10). The total score 63 
(excluding side-effects domain as these are only answered if the participant felt there were 64 
associated side-effects) was the primary outcome measure.  65 
Clinical assessment  66 
Height/arm span and weight were measured. Target height was calculated using: (mother + 67 
father’s height)/2 +13cm. Testicular size was assessed using a Prader orchidometer and 68 
pubertal staging determined using Tanner Staging criteria (11). Assessments were conducted 69 
by CW or TC and cross-checked > 75% patients.  70 
Biochemical gonadal / androgen status 71 
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Biochemical pubertal status was determined by measuring morning (pre-10.00) serum 72 
testosterone, luteinising hormone (LH) and follicle-stimulating hormone (FSH) 73 
concentrations at 0,6,12,18,24,27 and 30-33 months. Levels were also measured between 6 74 
and 9 months after their last testosterone injection, as part of routine clinical follow-up.  75 
Bone age 76 
Bone age was assessed at baseline and 2 years using a radiograph of the left wrist and 77 
reported by a consultant radiologist (12).  78 
Motor function and muscle strength 79 
All participants performed PUL (Version 2.0) for assessing upper limb performance (13) and 80 
ambulatory patients also undertook the NSAA (14).  81 
Bone mineral density  82 
DXA scans were conducted annually using a Lunar iDXA (GE Lunar Corp, Madison, WI USA) to 83 
assess lean versus total body mass and enable calculation of bone mineral content (BMC), 84 
adjusted for age, size and gender. Adjusted z-scores of lumbar spine (L1-4) and total body 85 
(minus head) were recorded.  86 
MRI data acquisition and image processing 87 
Imaging was performed on a 3.0T scanner (detailed protocols in Supplementary Methods). 88 
Briefly, quantitative Dixon FF imaging was collected using fivefold compressed sensing 89 
acceleration (15, 16). For the upper limb, quantitative Dixon FF imaging and T2 relaxation 90 
time imaging (a surrogate of muscle inflammation (17)) was performed and maps processed. 91 
Regions of interest (ROIs) were defined for the upper and lower limb for multiple image 92 
slices and FF and T2 relaxation times were calculated together as area-weighted averages.  93 
CSA and cCSA were also calculated to quantify the area of viable muscle tissue remaining 94 
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(18). Results are presented for muscle groups across all participants, and for individual 95 
participants across all their muscle groups. 96 
All participants consented to an MRI scan at baseline, 1 year and 2 years. Six healthy male 97 
controls, matched by bone age (as all participants in the trial had delayed puberty and bone 98 
age), underwent the same MRI protocol.  99 
Statistical Analysis and approvals  100 
This was an observational study and the primary outcome (treatment satisfaction) was not 101 
subject to a power calculation. The recruitment target was pragmatic and reflected the local 102 
population of boys with DMD and pubertal delay who were not already enrolled in a clinical 103 
trial. All data are presented as mean± SD unless stated otherwise. Independent t-tests were 104 
used to compare baseline measurements of DMD boys to healthy control participants.  105 
Paired t-tests (or Wilcoxon rank-sum techniques if variables not normally distributed) were 106 
used to compare outcome measures before and after testosterone administration. Statistical 107 
significance was taken to be p<0.05. Stata v15 was used for statistical analysis.  108 
The study was approved by York Research Ethics Committee. Informed consent was 109 
obtained from the patient if >16 years and from the parent/guardian with patient assent if 110 
<16 years. 111 
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Results 112 
Study flowchart 113 
 114 
Baseline characteristics 115 
Recruitment commenced in December 2015 until November 2016. 17 patients were 116 
approached, 16 agreed to take part and were screened and 15 were eligible (see flowchart 117 
and protocol (9)). The last participant’s final visit was February 2019. Participants were aged 118 
12.0-16.9 years (mean 13.8 years, mean bone age 9.4 years) at baseline (Table I). Controls 119 
were matched to bone age; their chronological age ranged from 7.9-12.9 years (mean 10.0 120 
years), all controls were prepubertal. 3/15 participants were non-ambulant at baseline. All 121 
participants had been on GC therapy for a mean of 8.1 years at recruitment (Table II); 122 
regimens were unchanged during the study. 123 
Two participants (15 and 16) in the study were happy with their pubertal development after 124 
18 months of intramuscular testosterone and stopped injections but completed all 125 
scheduled visits. These are highlighted with * in figures and tables.  126 
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Treatment satisfaction for medication questionnaire  127 
The mean total TSQM was 48.5 (SD 6.2, range 37-59) out of a possible 59 points, with similar 128 
scores in each domain (Table III and Figure I). To the nearest integer, the mean score for all 129 
but one treatment domain was 6 (‘very satisfied’). When considering time to effect, the 130 
mean score was 5 (‘satisfied’). Two patients felt that they had experienced side-effects from 131 
the IM testosterone regimen. Their responses corresponded with the adverse events profile 132 
recorded by the study team (Supplementary Results). 133 
Pubertal status 134 
All patients were either Tanner stage G1P1, G2P1 or G1P2 and had a testicular volume of 135 
<4mls at baseline. Initial testosterone levels were < 2.0nmol/l with suppressed LH and FSH 136 
levels (median LH <0.1IU/L (IQR <0.1, 0.1), median FSH 1.2IU/L (IQR 1.1, 1.8)). By the 2-year 137 
visit, patients were Tanner stage G4P4 to G5P5 and median testosterone level was 8.3nmol/l 138 
(IQR 5.7-17.9) 3-5 weeks after their last injection. Testicular volume was ≤ 5mls in all (mean 139 
2.8, SD 2.9, range 1.5-5 mls) after 2 years and LH/FSH levels remained suppressed (median 140 
LH <0.1IU/L (IQR 0.1, 0.1), median FSH <0.1IU/L (IQR 0.1, 1.2)). By 3 months after the last 141 
Sustanon injection, activation of the hypothalamo-pituitary axis (HPA) was evident with a 142 
significant increase in both LH and FSH (median LH 6.7IU/L (IQR 5.9, 8.8), p<0.01, median 143 
FSH 6.0IU/L (IQR 4.4, 8.0), p<0.01) compared to baseline. In keeping with this, the median 144 
testosterone level 3 months after the last injection was 7.5nmol/l (IQR 5.5-12.8- available in 145 
13/15 patients - two stopping treatment early). By 6-9 months after the last injection, the 146 
testosterone level was 9.7nmol/l (IQR 5.7-11.1). Mean testicular volume 6-9 months after 147 
last injection was 6.9ml (1.9), significantly greater than the baseline 2.2mls (SD 0.2; p<0.001). 148 
In keeping with this, LH and FSH levels also remained significantly raised compared to 149 
baseline at 5.3IU/l (IQR 3.2-5.9, p<0.001) and 7.9IU/L (IQR 5.1-10.4, p<0.001) respectively.  150 
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Muscle function 151 
The mean NSAA score at baseline for ambulant participants was 13.7 (SD 9.8) (Table IV). The 152 
mean PUL score at baseline was 33.9 (SD 6.7) and was not directly correlated with 153 
ambulatory status (Table I). PUL score was 30.9 (SD 8.7) at final assessment which was no 154 
different to baseline. Five participants lost ambulation during the 2-year study period, so 155 
that only 8 completed the NSAA at the final visit. For those with initial and final NSAA scores, 156 
mean initial NSAA score was 18.0 (SD 8.9, range 6-30) and final NSAA score 13.0 (SD 7.2, 157 
range 4-24). 158 
Anthropometric variables 159 
Baseline height z-score was -3.17 (SD 1.34) and -3.44 (SD 1.06) after 2 years. The mean 2-160 
year height gain was 8.8 cm (SD 5.2). The baseline BMI z-score was 2.16 (SD 0.90) with a 161 
mean change of -0.45 (SD -3.2) over 2 years, giving a final BMI z-score of 1.64 (SD 1.35). 162 
There was no change in fat mass or lean mass index during the study (Table IV, Figure III).  163 
Bone mineral density 164 
Initial lumbar spine size adjusted z-score was 0.22 (SD 2.21). After 2 years of testosterone 165 
treatment, the lumbar spine size-adjusted z-score was 0.35 (SD 2.21).  166 
Bone age 167 
Bone age advanced in all patients during the study period (Tables I and II); mean change was 168 
3.0 years (SD 1.7).  169 
Muscle MRI  170 
Cross-sectional comparison of DMD participants vs controls 171 
Data were obtained from the legs of 5 healthy controls and the arms of 6 healthy controls. 172 
Arm and leg muscle MRI data was obtained for 14 DMD participants who attended at 173 
baseline, 1 year and 2 years.  174 
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For leg muscle groups, the muscle FF was higher in DMD participants than controls (p = 175 
<0.001, Table VI), with a wide variation in leg muscle pathology of individuals (Figure IVA). 176 
The tibial bone marrow FF of DMD boys was also higher than controls at baseline (99.3% vs 177 
88.9%, p = 0.02, Table VI). 178 
All arm muscles had higher FF for DMD participants than controls (p <0.01, Table VII). The 179 
extent of arm muscle involvement varied considerably between individuals (Figure IVB). T2 180 
relaxation times were higher in DMD patients at baseline (p values <0.01) than controls 181 
(Table VII). The difference between T2 times of participants and controls at baseline was 182 
least marked for the UFG (1.3ms vs 2.6-3.0ms, Table VII). 183 
Longitudinal changes in MRI data 184 
The bone marrow FF was constant over time (Table VI). There were no significant 185 
longitudinal changes in mean FF of any individual leg muscle (Table VI), and when leg muscle 186 
groups were combined, there were no significant changes in FF during the 2-year period.  187 
When all muscle groups were combined, there were significant increases in both CSA and 188 
cCSA between baseline and 2 years (p<0.001 and p<0.01 respectively). When CSA of 189 
combined muscle groups for individuals was analysed, 8 participants had a significant change 190 
in CSA over 2-years. By individual muscle group, cCSA only increased in TA. 191 
Longitudinal changes in MRI arm data 192 
There was a significant increase in FF of the UFG (Table VII) over the 2-year period. Arm FF 193 
remained unchanged in most participants/muscle groups over the 2-year period (Table VII 194 
and Figure IVB). When all arm muscle groups were combined, both CSA and cCSA increased 195 
(p=0.004 and p=0.05). The CSA was greater in all four muscle groups at 2 years (Table VII).. 196 
The only significant change in arm cCSA over time was in the FEG, with increases at 1 and 2 197 
years compared to baseline (Table VII). 198 
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The T2 relaxation times for all groups except UFG decreased significantly at 2 years post-199 
baseline but remained higher than controls (Table VII). 200 
 201 
Discussion 202 
The newly revised standards of care highlight the importance of the timely recognition and 203 
management of pubertal delay in DMD (19) and this is the first study that has prospectively 204 
evaluated pubertal induction in adolescents with DMD. Our data support the use of 205 
androgen in DMD boys on GC with evidence of benefit in many of the parameters studied.  206 
Monthly incremental injections of Sustanon were well tolerated with adolescents being 207 
mainly ‘very satisfied’. The participant who awarded a value of 1 to the question, “Is the 208 
treatment easy to use?” probably did so in error, as they awarded the maximum score of 7 209 
to the other questions. The only domain in which the score was lower was ‘time to work’ 210 
where participants were ‘satisfied’.  211 
 212 
All patients were in late puberty after 2 years. The increase in gonadotropin levels and 213 
testicular volume, which occurred by 3 months and persisted at 6-9 months after the last 214 
Sustanon injection, suggested activation of the hypothalamo-pituitary gonadal (HPG) axis 215 
and endogenous testosterone production after the cessation of exogenous testosterone. 216 
There was variability in terms of testicular volume, androgen and gonadotrophin levels, 217 
suggesting that there may be additional factors affecting the HPG axis including relative 218 
sensitivity to GC (20, 21). It will be important to determine their ongoing gonadal and 219 
androgen status.  220 
 221 
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There was a mean height increase of 8cm over 2 years, substantially more than the median 222 
height velocity of only 0.45cm/year in the year preceding pubertal induction described 223 
previously in DMD (8). Short stature is a key concern in this population (6), and many 224 
adolescents would like to be taller and look more like their peers. Whilst a large height gain 225 
may not be advantageous (22), a small height gain during puberty is likely to be welcomed 226 
by the patients. 227 
 228 
Delayed bone age in adolescents with DMD is multi-factorial, but largely related to delayed 229 
puberty and growth retardation (23, 24). Bone age increased at a greater rate than 230 
chronological age suggesting that epiphyseal maturation was taking place despite the 231 
presence of pharmacological doses of GC.  232 
 233 
Low BMD and fracture are well-recognised complications in DMD, both as a consequence of 234 
the disease process itself and chronic GC use. Although this study was not powered to look 235 
in detail at bone health or body composition, it appears that the testosterone regimen 236 
stabilised BMD. However, as shown in Figure III, there was wide variability, with some 237 
participants having a marked increase in BMD, whilst others remained stable or decreased. 238 
Studies have shown that BMD decreases with age and GC use in DMD and falls further still 239 
when boys lose ambulation (25, 26, 27, 28). The process of puberty is vital for an increase in 240 
bone size and bone mineral content. Androgen deficiency is a risk factor for osteoporosis 241 
and fracture and early initiation of androgen therapy is associated with improved bone 242 
mineral density (29). Although fracture risk does not correlate directly with BMD, these data 243 
suggest a possible bone protective effect of testosterone therapy, despite ongoing GC use. 244 
Many boys lose ambulation after they fall and fracture and if muscle mass and bone density 245 
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can be optimised during puberty, ambulation may be maintained for longer. The change in 246 
mean PUL score over two years is consistent with published data (-3 points), (30) whereas 247 
the fall in mean NSAA score was slightly less than reported in the literature - mean drop of 4 248 
points a year (31).  249 
 250 
When arm muscle groups were combined, there were significant increases in both CSA and 251 
cCSA from baseline to 2 years. Only one participant (participant 7, non-ambulant at baseline) 252 
had a significant increase in overall FF of the arm. The arm FF remained unchanged over the 253 
2-year period, in contrast to the natural history of DMD. Our data contrast with a recent 254 
study of 15 non-ambulant boys with DMD (mean age 13.3 years) which found a progressive 255 
increase in FF (18). Only 7 boys completed that study and pubertal status was not recorded.  256 
 257 
When leg muscle groups were combined and compared between baseline and 2 years, there 258 
were also increases in both CSA and cCSA. FF in most participants and muscle groups were 259 
stable over the 2-year study period and only increased in one participant.  This challenges 260 
the results found in other studies (32, 33). 261 
 262 
The CSA of all four muscle groups in the arm increased significantly over 2 years, showing 263 
the muscle growth that we would expect. The cCSA (that area which is not fat replaced) on 264 
the other hand only increased significantly for the FEG, suggesting that in this muscle group 265 
the growth of muscle volume outpaced the disease process, whereby fat replaces muscle 266 
and the FF results support this. When all muscle groups were considered together, there was 267 
no significant increase in fat fraction and significant increases in CSA and cCSA for arm and 268 
legs: muscle growth at least kept pace with chronic destruction. By contrast, the cCSA did 269 
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not significantly increase in any of the arm muscle groups studied by Ricotti et al (18).  270 
 271 
The mean FF of the tibial bone marrow for the DMD boys was significantly higher than 272 
controls (Table III). Many factors may contribute to BMD reduction including progressive 273 
muscle weakness and GC use, which cause increased bone marrow adiposity (34, 35), 274 
probably through a diversion in the mesenchymal progenitor cell line with increased 275 
adipogenesis (36, 37). Bone marrow FF has been suggested as a potential biomarker in 276 
postmenopausal women with fragility fractures (38).  277 
 278 
The T2 relaxation times of all four compound muscle groups were significantly higher at 279 
baseline than controls, in keeping with an ongoing inflammatory process. This observation is 280 
consistent with some studies (39) but contrasts with others (32). The relaxation times for all 281 
groups except UFG (which was the least affected at baseline) decreased significantly at 2 282 
years but remained higher than those of the controls at baseline. This may indicate a 283 
reduction in the inflammatory process after testosterone supplementation, as similar results 284 
have been demonstrated after 3 months of GC therapy in DMD (40). Androgens are known 285 
to have an anti-inflammatory effect, partly via their role in cytokine-suppression (41, 42) and 286 
may have a disease-ameliorating role in addition to the more well characterised benefits of 287 
testosterone during puberty. It is possible, however, that T2 relaxation time may decrease 288 
once a boy loses ambulation and 5 boys lost ambulation over 2 years.(32).  289 
 290 
Limitations of the study 291 
Although we wanted to perform a randomised double-blinded clinical trial, the Research 292 
Ethic Committee felt that it would be inappropriate to withhold treatment for a period of 2 293 
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years in this cohort, particularly as our audit suggested that it was well-liked (8).  294 
Furthermore, physical development during puberty precludes the use of a placebo. By 295 
standardising the regimen, investigations and collection of the adverse event profile and 296 
safety data that are required as part of a rigorous clinical trial methodology, this has enabled 297 
us to systematically evaluate the tolerability and efficacy of this regimen. The study was 298 
small, and the recruitment target was pragmatic within a 1 year window at our centre. It was 299 
therefore underpowered to detect differences in some of the secondary outcomes such as 300 
BMAD and body composition.   301 
 302 
Conclusion 303 
A 2-year incremental regimen of 4-weekly intramuscular testosterone injections in pre-304 
pubertal boys with DMD was safe, well tolerated, associated with high satisfaction scores 305 
and resulted in endogenous gonadotropin release when exogenous testosterone was 306 
stopped. Height increased in most individuals and there was evidence to suggest a 307 
favourable impact on bone density, muscle morphology and muscle function. Our data 308 
support the routine use of exogenous androgen in boys with DMD who are on GC, as 309 
recommended in the revised DMD standards of care. It is unclear whether endogenous 310 
testosterone production will remain adequate in the longer term.    311 
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 488 
Table I Baseline characteristics of participants 489 
 490 
  Overall Ambulant  
(n=12) 
Non-
ambulant  
(n=3) 
 Mean (SD) 
Age at baseline (years) 13.8 (1.50) 13.7 (1.42) 14.4 (1.99) 
Bone age at baseline (years) 9.4 (2.2) 9.1 (2.2) 10.5 (2.3) 
Time on steroids (years) 8.4 (2.2) 8.4 (1.2) 8.7 (4.9) 
Deflazacort dose (mg/kg) n=9 0.55 (0.13) 0.56 (0.14) 0.44 (-) 
Prednisolone dose (mg/kg) n=6 0.47 (0.13) 0.51 (0.15) 0.41 (0.11) 
North Star Ambulatory Assessment score (NSAA) 13.7 (9.8) 13.7 (9.8) - 
Performance of the upper limb (PUL) score 33.9 (6.7) 34.3 (7.1) 32.7 (6.1) 
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 Initial 
age 
(years) 
Initial 
bone age 
(years) 
Final age 
(years) 
Final 
bone age 
(years)  
Change in 
bone age 
(years) 
GC 
regimen 
GC daily 
dose 
(mg/kg)  
Initial NSAA Final NSAA Initial PUL Final PUL 
1 14.75 8 16.75 12.5 4.5 D daily 0.52 7 8 36 31 
2 13.33 8 15.33 11 3 P daily 0.67 4 NA 26 17 
4 14.75 11 16.75 12.5 1.5 P daily 0.59 11 NA 41 34 
5 12.42 12.5 14.42 14 1.5 D daily 0.44 NA NA 34 39 
6 14.50 8 16.50 11 3 P daily 0.33 NA NA 38 29 
7 16.33 11 18.33 12.5 1.5 P daily 0.48 NA NA 26 20 
8 12.08 6 14.08 8 2 D daily 0.5 16 17 40 41 
9 12.33 10 14.33 12.5 2.5 D daily 0.49 30 24 42 42 
10 16.83 12 18.83 12.5 0.5 D daily 0.69 4 NA 20 22 
11 12.83 9.5 14.83 14.5 5 P 10 on/off 0.38 23 21 41 38 
12 14.17 6 16.17 11.5 5.5 D daily 0.69 13 4 28 22 
13 14.83 10 16.83 13.5 3.5 P daily 0.38 23 14 40 41 
14 12.25 12.5 14.25 14 1.5 D daily 0.3 1 NA 31 21 
15* 13.08 9 15.08 13 4 D daily 0.62 26 10 31 36 
16* 13.08 7 15.08 13 6 D daily 0.69 6 6 35 31 
Table II Individual patient characteristics D: deflazacort, P: prednisolone, NSAA: North Star ambulatory assessment, PUL: performance of the 
upper limb. * signifies the 2 patients that chose to stop testosterone treatment after 18 months 
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 Q1 (1-7) Q2(1-7) Q3 (1-7)  Q4 
(yes/no) 
Q5 (1-5) Q6 (1-5) Q7 (1-5) Q8 (1-5) Q9 (1-7) Q10 (1-7) Q11 (1-7) Q12 (1-5) Q13 (1-5) Q14 (1-7) 
 Effectiveness Side-effects Convenience Global satisfaction 
1 7 7 6 No     6 6 5 5 5 7 
2 7 7 5 No     6 6 6 4 No data 7 
4 7 7 7 No     7 5 5 4 3 6 
5 6 6 6 Yes 2 1 1 1 6 6 2 4 5 7 
6 7 7 7 No     7 7 7 5 5 7 
7 5 4 5 No     6 5 5 3 3 5 
8 4 3 5 No     6 6 7 4 3 5 
9 7 7 7 No     7 7 6 5 5 7 
10 6 4 5 No     7 7 7 3 3 5 
11 6 6 6 No     6 6 6 4 3 6 
12 6 6 6 Yes 1 1 1 1 6 6 5 5 5 6 
13 6 6 5 No     6 5 5 4 4 7 
14 5 5 5 No     7 7 6 5 5 7 
15* 4 7 5 No     5 5 5 3 2 5 
16* 4 4 2 No     1 7 7 3 3 7 
Table III TSQM questionnaire data. Q4 is a dichotomous response option with a conditional skip to Q9. Where a scale of 1-7 was used,  1 
indicates ‘extremely dissatisfied’, 7 indicates ‘extremely satisfied’. Within the scale of 1-5, 1 indicates ‘not at all’ while 5 indicates ‘extremely’.  
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 Initial 
T 
Initial 
LH 
Initial 
FSH  
Initial 
testic vol 
(mean) 
Initial 
Tanner 
stage 
T at end 
of 
regimen  
LH at 
end of 
regimen 
FSH at 
end of 
regimen 
Testic vol 
at end  
Tanner 
stage at 
end  
T 3 m 
after  
LH 3 m 
after  
FSH 3m 
after  
T 6-9m 
after  
LH 6-9 
m after  
FSH 6-9 
m after  
Testic vol 
6-9m 
after  
1 0.1 <0.1 1.1 1.5 G1P1 10 0.1 1.4 1.5 G5P4 15.2 8.8 3.6 14.7 3.2 5.5 4.75 
2 0.1 <0.1 1.3 2 G1P2 18.7 0.1 0.1 2.5 G4P4 21.8 5 1.8 11.1 3.6 2.5 10 
                  
4 1.9 3.3 3.8 3.5 G2P1 10.3 4.9 13.1 3 G4P4 19.5 6.2 11.2 9.7 3.2 11.1 8 
5 0.1 <0.1 0.5 1.5 G1P1 8.3 0.1 0.1 3 G4P4 7.5 9.8 4.4 5.7 2.6 4 8 
6 0.1 1.6 7.7 3 G1P2 17.9 0.1 0.1 4 G4P4 12.1 25.1 38.3 11.7 13.7 32.9 5 
7 0.1 <0.1 1.8 3.75 G1P1 5.2 0.5 0.1 3 G4P5 6.6 5.9 13.4 5.1 8.4 12.6 8 
8 0.1 <0.1 1.2 1.5 G1P2 20.7 0.1 0.1 3 G5P5 8.7 6.7 6.7 9.7 5.9 6.5 4 
9 0.1 <0.1 <0.1 2 G1P1 5.7 0.1 1.2 2 G5P4 5.5 7.6 8 7.9 5.3 8.6 10 
10 0.1 <0.1 <0.1 1.5 G1P2 6.9 0.1 0.1 2.5 G5P4 1.9 0.1 3.9 3.8 13.5 9.1 4 
11 0.1 <0.1 <0.1 2 G1P1 6.8 0.1 0.1 3 G5P5 6.7 6 6 10.1 5.5 8.4 - 
12 0.1 <0.1 1.1 2 G1P1 8.9 0.1 0.1 5 G5P5 11.7 7.8 5.9 9.8 4.2 5.1 5 
13 0.1 <0.1 1.1 2 G2P2 7.4 0.1 0.7 2 G4P4 6.9 10.1 3.6 8.3 3.1 2.0 - 
14 0.1 <0.1 1.3 1.5 G1P1 31.4 0.1 0.1 2.75 G5P5 1.3 2.3 1.8 4.9 5.7 10.4 - 
15* 0.1 <0.1 3.9 3.25 G2P1 4 0.1 0.1 2 G4P4 - - - 4.8 2.9 7.8 7.5 
16* 0.1 <0.1 1.1 2 G1P2 5.2 6.4 7.2 3 G5P5 - - - 12.8 5.3 7.9 6 
Table IV Pubertal characteristics * signifies the 2 patients that chose to stop testosterone treatment after 18 months. T measured in nmol/l, 
FSH and LH in IU/L, testicular volume in mls (mean of left and right volumes).
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 Before 
Testosterone 
After 
Testosterone 
 Mean (SD) 
Height (cm) 133.6 (10.7) 142.4 (7.4) 
Height z-score -3.17 (1.34) -3.44 (1.06) 
Target height (cm)  183.3 (4.6) 
Weight (kg) 48.3 (12.4) 52.8 (12.2) 
Weight z-score -0.19 (1.56) -0.94 (1.81) 
BMI (kg/m2) 26.8 (4.5) 26.3 (5.0) 
BMI z-score 2.16 (0.9) 1.64 (1.35) 
Lean mass index (kg/m2) 12.4 (2.3) 12.8 (2.9) 
Fat mass index (kg/m2) 13.6 (4.2) 12.5 (4.3) 
NSAA (if ambulant at both timepoints) 18 (8.88) 13 (7.23) 
PUL 33.9 (6.72) 30.9 (8.66) 
LS BMAC z-score 0.22 (2.21) 0.35 (2.21) 
Table V Outcome variables before and after a 2-year incremental regimen of intramuscular 
testosterone.  
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Muscle 
group 
DMD 
bl 
FF,% 
DMD 
1y 
FF,% 
DMD 
2y 
FF,% 
Control 
FF,% 
DMD bl 
CSA,mm2 
DMD 2y, 
CSA,mm2 
DMD bl, 
cCSA,mm2 
DMD 2y, 
cCSA,mm2 
BM 99.3 99.3 99.2 88.9* - - - - 
TA 11.7 11.2 11.9 2.0† 296 383† 265 343† 
MG 23.6 22.7 22.6 2.8§ 1216 1374 942 1090 
LG 28.7 28.0 28.5 2.5§ 549 644 371 443 
SOL 19.1 20.1 21.5 2.4‡ 1566 1611 1261 1274 
RF 51.9 53.9 51.5 1.6§ 500 548 237 258 
VL 50.8 51.5 51.8 2.0§ 994 1069 489 515 
BFLH 59.5 61.4 62.0 2.7§ 839 856 316 335 
ST 28.2 27.8 32.7 2.7‡ 508 612† 375 425 
SART 24.9 26.1 27.5 5.1§ 215 244* 163 178 
TOTAL 33.9 34.1 33.8 2.4‡ 6683 7341‡ 4419 4861† 
 
Table VI Longitudinal results for fat fraction (FF), cross-sectional area (CSA) and contractile 
cross-sectional area (cCSA) when each muscle group is considered separately for 14 
participants.* p < 0.05, † p < 0.01, ‡ p<0.001, § p < 0.0001 – p values in the control column 
are unpaired t-tests vs DMD baseline, p values in DMD 1 y and 2y are paired tests vs DMD 
baseline. Abbreviations : BM: bone marrow, TA: tibialis anterior, MG: medial gastrocnemius, 
LG: lateral gastrocnemius, SOL: soleus, RF: rectus femoris, VL: vastus lateralis, BFLH: biceps 
femoris long head, ST: semitendinosus, SART: sartorius.
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Muscle 
group 
DMD 
bl 
T2,ms 
DMD 
1y 
T2,ms 
DMD 
2y 
T2,ms 
Control 
T2,ms 
DMD 
bl 
FF,% 
DMD 
1y 
FF,% 
DMD 
2y 
FF,% 
Control 
FF,% 
DMD bl 
CSA,mm2 
DMD 2y, 
CSA,mm2 
DMD bl, 
cCSA,mm2 
DMD 2y, 
cCSA,mm2 
FEG (n=12) 31.0 31.0 29.5‡ 28.3§ 11.5 10.3 11.5 3.9‡ 397 501* 354 450* 
UEG (n=12) 32.4 32.1 31.2† 29.5‡ 13.6 16.1 18.8 3.4† 865 960* 749 808 
FFG (n=12) 31.5 31.2 29.6† 28.5§ 13.2 12.8 13.3 3.7† 849 911* 762 815 
UFG (n=13) 30.4 30.2 30.2 29.1* 17.0 21.2 24.8* 3.6† 564 630* 480 490 
TOTAL     12.3 11.8 14.6 3.6* 2675 3002† 2345 2563* 
 
Table VII Longitudinal results for fat fraction (FF, %), mean T2 relaxation time (ms), cross-sectional area (CSA, mm2) and contractile cross-
sectional area (cCSA, mm2), when each muscle group is considered separately for the participants. * p < 0.05, † p < 0.01, ‡ p<0.001, § p < 
0.0001 – p values in the control column are unpaired t-tests vs DMD baseline, p values in DMD 1 y and 2y are paired tests vs DMD baseline. 
Abbreviations: FEG: forearm extensor group, UEG: upper arm extensor group, FFG: forearm flexor group, UFG: upper arm flexor group 
 
